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Synthesis and biochemical evaluation of
cephalosporin analogues equipped with chemical
tethers†
Lisa M. Miller, *a Reyme Herman,b Ivan Gyulev,b Thomas F. Krauss,c
Gavin H. Thomasb and Anne-Kathrin Duhme-Klaira
Molecular probes typically require structural modifications to allow for the immobilisation or
bioconjugation with a desired substrate but the effects of these changes are often not evaluated. Here,
we set out to determine the effects of attaching functional handles to a first-generation cephalosporin. A
series of cephalexin derivatives was prepared, equipped with chemical tethers suitable for the site-
selective conjugation of antibiotics to functionalised surfaces. The tethers were positioned remotely
from the b-lactam ring to ensure minimal effect to the antibiotic's pharmacophore. Herein, the activity of
the modified antibiotics was evaluated for binding to the therapeutic target, the penicillin binding
proteins, and shown to maintain binding interactions. In addition, the deactivation of the modified drugs
by four b-lactamases (TEM-1, CTX-M-15, AmpC, NDM-1) was investigated and the effect of the tethers
on the catalytic efficiencies determined. CTX-M-15 was found to favour hydrolysis of the parent
antibiotic without a tether, whereas AmpC and NDM-1 were found to favour the modified analogues.
Furthermore, the antimicrobial activity of the derivatives was evaluated to investigate the effect of the
structural modifications on the antimicrobial activity of the parent drug, cephalexin.
Introduction
The controlled functionalisation of surfaces is imperative for
the preparation of functional materials. This a key step in the
preparation of many (bio)sensors, for example, which are
designed for selective and sensitive detection of analytes. The
immobilisation or bioconjugation of a molecular probe oen
requires structural modication to introduce a functional
handle, able to react with a desired substrate. A common
approach is to attach a linker to the probe, such as a bifunc-
tional polyethylene glycol (PEG), with orthogonal functional
groups that allows for controlled reaction with the probe and
with the desired substrate.1 However, the effect of such modi-
cations on the function of a probe are oen not evaluated,
even though binding interactions are likely to be affected.
Consequently, opportunities to gain insights into the structure–
activity relationships (SAR) are missed.
With the difficulties faced in the development of novel
antibiotics and the increasing challenges of ghting against
antibiotic resistance,2,3 investigations into the SAR of antibiotic
analogues could reveal valuable information. The b-lactam
antibiotics are widely used and are typically considered to be
one of the safest classes of antibiotics.4 Since their discovery,
there has been extensive research carried out into the derivati-
sation of the b-lactam scaffold, resulting in the successful
development of numerous antibiotics.5,6
Recently, we demonstrated the ability of surface bound b-
lactam drugs to be recognised by the therapeutic target proteins
as well as enzymes produced by resistant bacteria.7 In order to
attach the antibiotic molecule to the surface, an analogue of
cephalexin (1) was prepared featuring a maleimide group
attached via a PEG linker (2), Fig. 1. Studies of the surface-
bound antibiotic demonstrated that b-lactamases and a peni-
cillin binding protein (PBP) were able to recognise and bind the
immobilised drugs. Here, we set out to investigate the effect of
the addition of a chemical tether on the properties of the parent
compound, thus contributing new SAR information.
Results and discussion
Chemistry
Compound design. The modications to 1 described herein
were performed via the amine of the molecule. This position
was chosen to minimise the effect of the tether on the phar-
macophore, the b-lactam ring. The amine motif provided
a functional handle for the addition of the desired chemical
tether through amidation reactions, allowing access to
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a selection of compounds with reactive pendant groups. In
addition to the previously reported compounds 2 and 3,7
a further seven analogues were synthesised, Fig. 1. Compounds
2–6 were designed to include commonly employed functional
groups that are used in biocompatible reactions with surfaces
and other substrates of interest.
Compounds 2 and 3 both feature a maleimide; this motif is
a prevalent functional handle used for selective reaction
through conjugation with thiol groups.8 Another commonly
used bio-compatible reaction is the copper-catalysed click
reaction in which an alkyne, such as in compound 4, reacts with
an azide to form a triazole.9 For the direct attachment to gold
surfaces disuldes, such as the lipoic acid tether of compound
5, are ubiquitous.10 Whereas, for the attachment to a protein, or
another source of amine functional groups, N-hydrox-
ysuccinimide (NHS) esters are common.11 Compounds with this
activated ester, as in compound 6, react readily with lysine
residues and other amines, providing attachment through the
formation of an amide bond.
NHS-esters, such as compound 6, are known to have a short
half-life in aqueous media;11 thus, the hydrolysis product with
the carboxylic acid was prepared for comparison, compound 7.
Three further control compounds were synthesised: one to test
the effect of a small modication with the acetyl group of
compound 8, whereas the tert-butyloxycarbonyl (Boc) group of
compound 9 was designed to test the effect of a large sterically
demanding group in this position. Lastly, compound 10 was
included featuring a small aliphatic tether with a terminal
amine group. By attaching the tethers via an amide linker in
compounds 2–9, the amine of the parent antibiotic is lost.
Therefore, compound 10 was included to determine the effects
of introducing an amide and a short exible tether, while
maintaining an amine group.
Compound synthesis. The two maleimide analogues (2 and
3) were prepared as previously reported.7 All analogues were
prepared by addition of the tethers to the parent antibiotic, as
described in Scheme 1. Compounds 4 and 5 were prepared from
reaction of 1 with the NHS-esters of the corresponding tether,
intermediates 16 and 18. In the preparation of compound 6, the
previously reported acid (20)12 was used to allow for the desired
amidation via the acid chloride, while maintaining the NHS-
ester. Compounds 7, 8, and 9 were prepared by reaction with
the required anhydride reagent: glutaric anhydride, acetic
anhydride and Boc anhydride, respectively. Finally, compound
10 was prepared in three steps from the N-Boc protected 5-
aminovaleric acid 21, Scheme 1. All compounds were charac-
terised by 1H, 13C NMR, IR spectroscopy, and HRMS. Purity of
compounds for in vitro and in vivo testing was determined using
HPLC or QNMR.
Fig. 1 Chemical structures of the parent antibiotic cephalexin (1) and
the nine analogues (2–10) evaluated for the effects of addition of
a chemical tether.
Scheme 1 Synthesis of tethered analogues. (a) NHS, DCC, DCM; (b) 1,
DIPEA, MeCN; (c) NHS, DMAP, THF; (d) (i) (ClCO)2, DMF, DCM, (ii) 1,
anhydrous pyridine, MeCN; (e) 1, Et3N, MeCN; (f) TFA, TES, DCM.
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Biological evaluation
PBP binding assay. A thermal shi assay was used to inves-
tigate the binding of the cephalexin analogues to the thera-
peutic target, PBP, in vitro. This assay provides a fast and
inexpensive method of detecting a ligand binding to a protein of
interest. Briey, the protein is gradually heated in the presence
of a uorescent dye that binds non-specically to the hydro-
phobic surfaces. As the protein unfolds, hydrophobic surfaces
within the protein are revealed, causing the dye to uoresce. A
change in the melting temperature (Tm) when the protein is
heated in the presence of a ligand, indicates a protein–ligand
interaction. Fig. 2 shows the results of the thermal shi assay
carried out using recombinant PBP3 and PBP4 with compounds
1–10. The PBPs can be divided into two main categories: high
molecular mass (HMM) and low molecular mass (LMM).13 PBP3
was chosen as a representative HMM PBP, and PBP4 as
a representative LMM PBP. Cephalexin (1) has been previously
reported to show good binding affinities for both PBP3 and
PBP4.14 Penicillin (11) and cefpodoxime (12) were included as
positive controls.
The results from this assay showed that all of the analogues
tested caused an increase in the Tm with PBP3, thus increasing
the thermostability of this particular PBP upon binding.
Whereas, with PBP4 there was either no shi or a small decrease
in the Tm observed, indicating the ligands are facilitating the
unfolding of the protein. Previously reported thermal shi
assays with PBPs have noted both increases and decreases in Tm
of the protein aer the binding of different b-lactam
analogues.15–17
Further thermal shi studies were carried out to approxi-
mate the affinities of compounds 1–12 with PBP3. PBP3 was
selected for this study as this particular PBP is essential for cell
division in E. coli, making PBP3 an important target for b-lac-
tam antibiotics.13 By measuring the Tm values of PBP3 with
compounds 1–12 at a range of ligand concentrations, aer
a constant incubation time, the equivalents of each ligand
required to cause a shi greater than half the Tm value (Tm1/2)
were determined, Fig. 3. Using this assay, it was determined
that 75 equivalents of compound 1 was required to achieve
>Tm1/2 but with analogues 2–10, fewer equivalents were
required. This study also showed that penicillin (11) has a great
affinity for PBP3 than cephalexin (1), which is consistent with
previously reported data.14 The results, as shown in Fig. 3,
suggest that addition of the tethers has improved the binding
affinity of analogues 2–10 with PBP3, compared to that of the
parent antibiotic 1.
b-Lactamase kinetics studies. Previously reported SAR
around the b-lactam class of antibiotics has shown that
increased steric bulk at the 7-position of cephalosporins can
reduce the rates of drug hydrolysis by the b-lactamases.18 Many
of the b-lactam antibiotics from the later generations, for
example cefpodoxime (12, Fig. 4), which are stable in the pres-
ence of many b-lactamases, feature sterically demanding groups
in this position. The SAR of cephalosporins suggested that
increasing the steric bulk at the 7-position of cephalexin (1) will
provide resistance to b-lactamase-mediated hydrolysis. There-
fore, it was hypothesised that analogues 2–10, which all feature
tethers at this position, would have improved stability,
compared to that of the parent drug 1.
To investigate the effect that the addition of the chemical
tethers reported herein had on the rate of b-lactamase-mediated
hydrolysis, a previously reported absorbance assay was
employed.19 The rates of hydrolysis were measured by the
decrease in absorbance at 260 nm caused by hydrolysis of the b-
lactam ring. The rates of hydrolysis weremeasured and the initial
Fig. 2 Thermal shift assay of compounds 1–12 with PBP3 and PBP4.
Melting temperatures (Tm) were calculated from the average of three
measurements, withs.d. error.DTmwas calculated by subtracting the
Tm of the PBP. The assay protocol is provided in the Experimental
section.
Fig. 3 Relative affinities for compounds 1–12 with PBP3. Ligand
equivalents required to cause >Tm1/2 shift. Lower equivalents conveys
higher affinity. The assay protocol is provided in the Experimental
section.
Fig. 4 The cephalosporin structure. Cefpodoxime (12), has increased
stability in the presence of b-lactamases due to the increased steric
bulk at the 7-position.
This journal is © The Royal Society of Chemistry 2020 RSC Adv., 2020, 10, 36485–36494 | 36487
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velocity of each determined. The high Km values prevented
determinations of the Vmax values, therefore the catalytic effi-
ciencies (kcat/Km) were determined using v ¼ (kcat/Km)[E][S].
20,21
The relative catalytic efficiencies, with respect to the (kcat/Km)
value for the parent antibiotic cephalexin (1), were used to
compare the reaction specicities of four selected b-lactamases
with the tethered analogues, Table 1.
The b-lactamase enzymes are well studied, with over 2500
unique proteins identied.22 This vast family of enzymes can be
categorised into subsets (class A, B, C, or D), based on their
protein sequence. Initial tests were carried out using TEM-1,
one of the most common b-lactamases found in Gram-
negative bacteria.23 This class A b-lactamase is able to hydro-
lyse penicillins and the early generations of cephalosporins. Of
the ten analogues tested, compound 9 was the preferred
substrate with TEM-1, suggesting that the large Boc group
attached to this analogue does not hinder the hydrolysis. The
least preferred substrate with TEM-1 was compound 2, which is
the largest of the compounds tested with a PEG tether. However,
there was no clear trend in the relative catalytic efficiencies of
compounds 1–10 with TEM-1.
As with TEM-1, compound 2 was also observed to be the least
preferred substrate with CTX-M-15, an extended spectrum b-
lactamase (ESBL) from class A. ESBLs are plasmid-encoded
enzymes that confer increased antibiotic resistance to
commonly used antibiotics.24 CTX-M-14 and CTX-M-15 are the
most prevalent ESBLs and known to contribute towards many
cases of multidrug resistant infections.25,26 The relative catalytic
efficiencies showed that the two more preferred substrates of
CTX-M-15 had no tether (compound 1) and the smallest tether
tested, the acetyl group (compound 8). This trend suggests that
modications to this point of the antibiotic has a direct effect
on the stability against hydrolysis by CTX-M-15. Thus structural
modications to this point of the antibiotic could be an effective
strategy in the production of antibiotics with increased stability
to this ESBL.
The relative catalytic efficiencies of compounds 1–10 with
AmpC demonstrated that introduction of the tethers resulted,
surprisingly, in increased substrate activity against the modi-
ed b-lactam. AmpC is a class C b-lactamase known to confer
resistance to the cephalosporins such as cephalexin (1), as well
as cephamycins and carbapenems.22 Compound 2 was less
favoured than 1, but all other analogues had a signicantly
higher catalytic efficiency than the parent antibiotic, particu-
larly compound 7, which featured a glutaric acid tether. This
observation suggests that modications to this point of the
antibiotic results in reduced stability to AmpC mediated
hydrolysis. This is in contrast to the trend observed with CTX-M-
15, showing that the effect of these structural modications, to
the 7-position of cephalexin (1), is specic to the b-lactamase
under investigation.
Further tests were carried out to investigate the effects of the
tethers on the hydrolysis by a metallo-b-lactamase, NDM-1. The
metallo-b-lactamases are known to hydrolyse penicillins, ceph-
alosporins and even last resort carbapenems. These class B b-
lactamases hydrolyse b-lactams by an alternative mechanism
that relies on one or two zinc ions present in the active site.27
These enzymes are oen produced by clinical strains with
multiple forms of resistance that are only susceptible to last line
antibiotics.28 The relative catalytic efficiencies of compounds 1–
10 with NDM-1 demonstrated that introduction of the tethers to
the antibiotic resulted in increased substrate activity, the same
trend that was observed with AmpC. These results suggest that
modications to this point of the antibiotic results in reduced
stability to NDM-1 mediated hydrolysis and should be avoided
in developing cephalexin (1) analogues stable to NDM-1.
In vivo assays. The in vitro assays demonstrated that the
modied analogues were able to interact with the therapeutic
target proteins (PBP3 and PBP4) and four selected b-lactamases
(TEM-1, CTX-M-15, AmpC, and NDM-1), as shown in Fig. 2, 3
and Table 1. Further testing was carried out in vivo to determine
whether the tethered compounds had any antibacterial activity.
Table 2 summarises theMIC values determined for 1–12, MBC50
data is included in the ESI.†
The activity of 1–12 was investigated with growth assays
against Staphylococcus aureus (NCTC 6571). S. aureus is a viru-
lent Gram-positive pathogen that can cause a wide range of
infections in humans.29,30 Each compound was tested at 400–6
mM concentrations, with lower concentrations tested as
required. All tethered analogues were still able to inhibit the
growth of this strain of S. aureus; however, the tethers were
detrimental to the antimicrobial activity against this Gram-
positive bacteria, with all but one MIC value (compound 9)
determined to be greater than that of the parent antimicrobial
1.
Further growth assays tested 1–12 against Escherichia coli
BW25113, a K-12 strain. E. coli K-12 is the workhorse of many
microbiology laboratories; however, E. coli is a versatile Gram-
negative bacterium and the evolution of pathogenic E. coli can
cause a number of harmful infections in humans.31 Only the
parent antibiotic 1 and the two control compounds 11 and 12
were observed to have antimicrobial activity against E. coli. Thus
showing that the addition of the chemical tethers has a signi-
cant detrimental effect on the activity of the antibiotic against E.
coli.
Physicochemical properties. Since the abilities of 2–10 to
bind the therapeutic target had been conrmed in vitro (Fig. 2),
Table 1 Relative catalytic efficiencies (kcat/Km)
a of compounds 1–10
with TEM-1, CTX-M-15, AmpC, and NDM-1
Compound TEM-1 CTX-M-15 AmpC NDM-1
1 1.0 1.0 1.0 1.0
2 0.2 0.2 0.7 1.1
3 1.5 0.3 5.7 1.7
4 1.2 0.3 17 4.9
5 0.6 0.8 11 3.7
6 0.4 0.5 4.3 1.2
7 2.2 0.5 19 5.2
8 1.8 1.0 11 4.7
9 2.6 0.3 4.7 1.3
10 0.3 0.6 13 3.5
a Catalytic efficiencies (kcat/Km) were determined using v ¼ (kcat/Km)[E]
[S].20,21 Relative values calculated as a ratio with respect to cephalexin, 1.
36488 | RSC Adv., 2020, 10, 36485–36494 This journal is © The Royal Society of Chemistry 2020
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the in vivo results suggest that the tethered analogues may be
unable to access the PBPs within the periplasm of E. coli. To
gain a further insight into the effects of the chemical tethers,
the physicochemical properties of each compound was evalu-
ated. The compounds were scored on the properties favourable
for accumulation in Gram-negative bacteria, based on the
observations of Richter et al. who reported that there are three
key properties in predicting the accumulation: a primary amine,
low globularity, and high rigidity.32,33 In order to score the
likelihood of the compounds accumulating, each was scored
based on the “eNTRy rules” reported by Richter et al.: number of
primary amines (NoA)$ 1; globularity (Glob)# 0.25; number of
rotatable bonds (NoRB) # 5, Table 3. The predicted accumula-
tion scores were determined to be below ideal for all of the
tethered analogues (2–10), primarily due to the loss of the
amine group used in the introduction of the tethers via an
amide bond. Compound 10, whichmaintained an amine group,
failed based on the increased NoRB. Chemical tethers are oen
designed with exibility to favour the subsequent reactions with
other substrates, particularly in examples that form a mono-
layer on a surface. However, this exibility increases the NoRB,
reducing the rigidity of these analogues, which reduces the
likelihood of accumulation. Based on the predicted accumula-
tion scores of Table 3, all of the tethered analogues are expected
to have lower activity than that of 1 against Gram-negative
bacteria. As shown in Table 2, this was found to be true for all
tethered analogues, 2–10. Compounds 8 and 10 both scored two
but for different reasons: compound 8 lacked the required
amine whereas compound 10 exceeded the limit for NoRB. The
growth assay results showed that both compounds were inactive
against E. coli demonstrating the importance of these two
criteria of the “eNTRy rules”. By using more rigid tethers and
including an amine group, it may be possible to produce teth-
ered analogues that are active against Gram-negative bacteria.
However, the criteria compared in Table 3 fail to predict the
measured antimicrobial activity of 11 and 12 against E. coli. A
reliable method of predicting antimicrobial activity is very
much coveted, but it is yet to be achieved due to the complex
factors involved.32–35
Summary and conclusions
A series of cephalexin (1) analogues equipped with chemical
tethers was evaluated for binding to the therapeutic target, the
penicillin binding proteins, and shown to maintain binding
interactions in vitro. Further investigations with four b-lacta-
mases (TEM-1, CTX-M-15, AmpC, and NDM-1) were carried out
and revealed that the modications affected each enzyme's
catalytic rates differently. With TEM-1, there was no clear trend
in the catalytic efficiencies of 1–10. CTX-M-15 was found to
favour hydrolysis of the parent antibiotic without a tether, thus
demonstrating that modications to this position of 1 could
produce antibiotics with increased stability to this ESBL.
Conversely, both AmpC and NDM-1 were found to favour the
modied analogues suggesting that these types of structural
modications should be avoided in the design of analogues
stable to AmpC and/or NDM-1. The tethers were found to lower
the antimicrobial activities when testing against S. aureus and
cause complete loss of activity against E. coli. The loss of activity
against E. coli was consistent with previously reported obser-
vations linking the globularity, rigidity, and amine functionality
of antibiotics with accumulation in Gram-negatives.
These results show that the addition of the tethers directly
affected the properties of the antibiotic, thus highlighting the
importance of evaluating the changes that occur from modi-
fying molecular probes. Most notably, the effect of the tethers
on the rate of b-lactamase-mediated hydrolysis was specic to
the b-lactamase under investigation. This suggests that
Table 2 MIC results for compounds 1–12
Compound
MICa
S. aureus
(NCTC 6571)
E. coli
(BW25113)
1 18.9 mM 94.9 mM
2 92.6 mM >400 mMb
3 55.8 mM >400 mMb
4 35.0 mM >400 mMb
5 24.9 mM >400 mMb
6 82.9 mM >400 mMb
7 81.4 mM >400 mMb
8 59.0 mM >400 mMb
9 11.0 mM >400 mMb
10 51.4 mM >400 mMb
11c 97.7 nM 371 mM
12c 20.9 mM 7.7 mM
a MIC values were determined aer 16 h incubation. Dose–response
curves are provided in the ESI, MIC data was analysed using
GraphPad Prism (version 8.3.0). b MIC not determined in
concentration range tested (up to 400 mM). c Penicillin (11) and
cefpodoxime (12).
Table 3 Score for the likelihood of accumulation inside Gram-nega-
tive bacteria
Compound NoAa Globb NoRBc Scored
1 1 0.057 4 3
2 0 0.022 30 1
3 0 0.064 11 1
4 0 0.098 7 1
5 0 0.083 10 1
6 0 0.035 11 1
7 0 0.085 9 1
8 0 0.134 5 2
9 0 0.133 7 1
10 1 0.088 9 2
11e 0 0.095 4 2
12e 0 0.068 7 1
a Number of primary amines (NoA). b Globularity (Glob). c Number of
rotatable bonds (NoRB). d Score out of three based on the following
criteria: NoA $ 1; Glob # 0.25; NoRB # 5. e Penicillin (11) and
cefpodoxime (12) included for comparison. NoRB determined using
Marvin 17.21.0, ChemAxon. Glob determined using https://entry-
way.org.
This journal is © The Royal Society of Chemistry 2020 RSC Adv., 2020, 10, 36485–36494 | 36489
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modifying the 7-position of 1 could be key in the development
of surface-bound antibiotics for the selective detection of b-
lactamases associated with multidrug resistant infections, such
as NDM-1.
Experimental
Chemistry
General experimental. Analytical thin layer chromatography
(TLC) was performed with EM Science silica gel 60 F254
aluminium plates. Visualisation was carried out using a UV
lamp (254 nm) and by immersion in potassium permanganate
(KMnO4), followed by heating using a heat gun. Organic solu-
tions were concentrated by rotary evaporation at 40–45 C.
Purication of reaction products by ash column chromatog-
raphy was carried out using Fluka Silica, pore size 60A, 220–440
mesh, 35–75 mm.
Materials. Unless otherwise noted, all purchased materials
were used without purication. All standard solvents were
purchased from Sigma Aldrich. All standard acids, bases, and
drying agents were purchased from Fisher Scientic. NHS and
N,N-diisopropylethylamine (DIPEA) were purchased from Acros
Organics. Cephalexin monohydrate and Boc2O were purchased
from Fluorochem. Pentynoic acid, N,N0-dicyclohex-
ylcarbodiimide (DCC), lipoic acid, glutaric anhydride, oxalyl
chloride, and Et3N were purchased from Sigma Aldrich. DMAP
and 5-(Boc-amino)pentanoic acid were purchased from TCI.
Instrumentation. 1H and 13C NMR spectra were recorded on
a Jeol ECS 400 (400 MHz for 1H, 101 MHz for 13C) at ambient
temperature. Chemical shis are reported relative to residual
solvent peaks and coupling constants (J) are given in hertz.
High-resolution ESI mass spectra were recorded on a Bruker
microTOF electrospray mass spectrometer. Infrared (IR) spectra
were recorded on a PerkinElmer Spectrum Two (ATIR). Analyt-
ical HPLC measurements were performed on a Shimadzu HPLC
system (Prominence) equipped with a LC-20AD pump, SIL-20A
autosampler, DGU-20AS degasser, CTO-20AC column oven,
CBM-20A communication bus module and SPD-M20A diode
array detector using an Athena C18-WP column (100 A, 4.6 
250 mm, 5 mm). Eluent gradient: 5–95%MeCN/H2O with a 0.1%
formic acid modier, over 15 minutes.
Compound synthesis
Preparations of 2 and 3. Compound 2 (6R,7R)-7-((R)-30-(2,5-
Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-4,8,25-trioxo-2-phenyl-
6,12,15,18,21-pentaoxa-3,9,24-triazatriacontanamido)-3-methyl-
8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid and 3,
(6R,7R)-7-((R)-2-(6-(2,5-dioxo-2,5-dihyrdo-1H-pyrrol-1-yl)
hexanamido)-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid were previously
reported.7
Preparation of 4. (6R,7R)-3-Methyl-8-oxo-7-[(2R)-2-(pent-4-yn
amido)-2-phenylacetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid. To a stirred solution of pentynoic acid (15)
(100 mg, 1.020 mmol, 1 equiv.) in anhydrous DCM (1 mL, 1 M) at
0 C was added NHS (123 mg, 1.071 mmol, 1.05 equiv.). A solution
of DCC (221 mg, 1.071 mmol, 1.05 equiv.) in DCM (1 mL) was
added slowly. The reaction mixture was then allowed to warm to
room temperature. Aer 16 h, the urea precipitate formed during
the reaction was ltered off, and the lter cake washed with DCM.
The ltrate was concentrated under reduced pressure to afford
2,5-dioxopyrrolidin-1-yl pent-4-ynoate (16), which was used
without further purication. The residue was dissolved in anhy-
drous MeCN (10 mL) and cephalexin monohydrate (338 mg,
0.927 mmol, 0.9 equiv.) was added. The mixture was cooled in an
ice bath followed by the slow addition of DIPEA (443 mL,
2.550 mmol, 2.5 equiv.). Once the addition was complete, the ice
bath was removed, and the reaction was allowed to stir at room
temperature for 2 h at which time the reaction appeared complete
by TLC. The reaction mixture was concentrated under reduced
pressure, dissolved in EtOAc (20 mL), and washed with 0.1 M HCl
(2  20 mL). The organic layer was collected and concentrated to
a cream solid, which was the puried by trituration from diethyl
ether to afford (6R,7R)-3-methyl-8-oxo-7-[(2R)-2-(pent-4-ynamido)-
2-phenylacetamido]-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic acid (4) (277mg, 70% yield) as a white solid.
1HNMR (400MHz, DMSO-d6) d 9.32 (d, J¼ 8.4 Hz, 1H), 8.65 (d, J¼
8.2 Hz, 1H), 7.44 (d, J¼ 7.0 Hz, 2H), 7.37–7.25 (m, 3H), 5.71 (d, J¼
8.2 Hz, 1H), 5.62 (dd, J ¼ 8.3, 4.7 Hz, 1H), 4.96 (d, J ¼ 4.7 Hz, 1H),
3.46 (d, J ¼ 18.5 Hz, 1H), 3.28 (d, J ¼ 18.4 Hz, 1H), 2.76 (t, J ¼
2.6 Hz, 1H), 2.47–2.40 (m, 2H), 2.39–2.31 (m, 2H), 1.98 (s, 3H). 13C
NMR (101 MHz, DMSO-d6) d 170.8, 170.2, 164.1, 163.6, 138.3,
129.7, 128.2, 127.6, 127.1, 122.8, 83.8, 71.4, 58.4, 57.2, 55.6, 33.7,
28.9, 19.4, 14.1. HRMS: exact mass calculated for [M  H]
(C21H20N3O5S) requires m/z 426.1129, measured m/z 426.1148. IR
(neat): 3280, 3010, 1762, 1721, 1650, 1643, 1539, 1377, 1218, 1108,
1070 cm1. HPLC purity (254 nm): 96%.
Preparation of 5. (6R,7R)-7-[(2R)-2-[5-(1,2-Dithiolan-3-yl)
pentanamido]-2-phenylacetamido]-
3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
acid. To a stirred solution of lipoic acid (17) (1 g, 4.854 mmol, 1
equiv.) in anhydrous DCM (30mL, 0.2 M) at 0 C was added NHS
(614 mg, 5.340 mmol, 1.1 equiv.). A solution of DCC (1.3 g,
6.311 mmol, 1.3 equiv.) in DCM (10 mL) was added slowly. The
reaction mixture was then allowed to warm to room tempera-
ture. Aer 16 h, the urea precipitate formed during the reaction
was ltered off, and the lter cake washed with DCM. The
ltrate was concentrated under reduced pressure to afford
a yellow residue. Recrystallisation from EtOAc : hexane (1 : 1)
afforded 2,5-dioxopyrrolidin-1-yl 5-(1,2-dithiolan-3-yl)penta-
noate (18) (978 mg, 66%) as an off-white solid. 1H NMR (400
MHz, chloroform-d) d 3.58 (dq, J ¼ 8.2, 6.4 Hz, 1H), 3.25–3.06
(m, 2H), 2.84 (d, J ¼ 4.1 Hz, 4H), 2.63 (t, J ¼ 7.3 Hz, 2H), 2.47
(dtd, J ¼ 13.1, 6.6, 5.4 Hz, 1H), 1.93 (dq, J ¼ 12.7, 6.9 Hz, 1H),
1.79 (p, J ¼ 7.4 Hz, 2H), 1.77–1.65 (m, 2H), 1.63–1.52 (m, 2H).
13C NMR (101 MHz, chloroform-d) d 169.3, 168.6, 56.2, 40.3,
38.7, 34.6, 30.9, 28.5, 25.7, 24.5. 1H and 13C are consistent with
previously reported data.36 HRMS: exact mass calculated for [M
+ Na]+ (C12H17NNaO4S2) requires m/z 326.0491, measured m/z
326.0490. IR (neat): 2934, 2915, 2861, 1809, 1780, 1729, 1630,
1574 cm1. Mp 93–94 C, consistent with reported data.37
2,5-Dioxopyrrolidin-1-yl 5-(1,2-dithiolan-3-yl)pentanoate
(18) (294 mg, 0.971 mmol, 1 equiv.) was dissolved in anhydrous
MeCN (20 mL, 0.05 M) and cephalexin monohydrate (235 mg,
0.647 mmol, 0.66 equiv.) was added. The mixture was cooled in
36490 | RSC Adv., 2020, 10, 36485–36494 This journal is © The Royal Society of Chemistry 2020
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
2 
O
ct
ob
er
 2
02
0.
 D
ow
nl
oa
de
d 
on
 1
0/
5/
20
20
 3
:4
8:
59
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
an ice bath followed by the slow addition of DIPEA (169 mL,
0.971 mmol, 1 equiv.). Once the addition was complete, the ice
bath was removed and the reaction was allowed to stir at room
temperature for 6 h. The reaction mixture was then concen-
trated under reduced pressure and triturated using 5% DCM/
diethyl ether to afford (6R,7R)-7-[(2R)-2-[5-(1,2-dithiolan-3-yl)
pentanamido]-2-phenylacetamido]-
3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
acid (5) (190 mg, 55%) as a white solid. 1H NMR (400 MHz,
DMSO-d6) d 9.29 (d, J ¼ 8.3 Hz, 1H), 8.55 (d, J ¼ 8.3 Hz, 1H),
7.48–7.39 (m, 2H), 7.35–7.23 (m, 3H), 5.70 (d, J ¼ 8.3 Hz, 1H),
5.61 (dd, J ¼ 8.4, 4.7 Hz, 1H), 4.95 (d, J ¼ 4.7 Hz, 1H), 3.65–3.54
(m, 1H), 3.46 (d, J¼ 18.2 Hz, 1H), 3.27 (d, J¼ 18.2 Hz, 1H), 3.22–
3.06 (m, 2H), 2.40 (dt, J ¼ 12.5, 6.2 Hz, 1H), 2.22 (t, J ¼ 7.4 Hz,
2H), 1.98 (s, 3H), 1.90–1.79 (m, 1H), 1.76–1.57 (m, 2H), 1.57–1.46
(m, 2H), 1.34 (q, J¼ 7.4, 6.9 Hz, 2H). 13C NMR (101 MHz, DMSO-
d6) d 171.9, 170.9, 164.0, 163.6, 138.4, 128.2, 127.6, 127.1, 58.4,
57.2, 56.2, 55.5, 38.1, 34.7, 34.1, 33.4, 28.9, 28.3, 25.3, 25.0, 24.5,
19.4. HRMS: exact mass calculated for [M + Na]+ (C24H29N3-
NaO5S3) requires m/z 558.1162, measured m/z 558.1152. IR
(neat): 3287, 2927, 1766, 1642, 1513, 1360, 1219 cm1. HPLC
purity (254 nm): 95%.
Preparation of 6. (6R,7R)-7-[(2R)-2-{5-[(2,5-Dioxopyrro
lidin-1-yl)oxy]-5-oxopentanamido}-2-phenylacetamido]-
3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
acid. NHS (1 g, 8.772 mmol, 1 equiv.) and DMAP (1 g,
8.772 mmol, 1 equiv.) were dissolved in anhydrous THF (50 mL)
and cooled in an ice bath. Glutaric anhydride (19) (1.6 g,
13.158 mmol, 1.5 equiv.) was then added portion-wise and the
resulting reaction mixture was allowed to warm to room
temperature. Aer a further 4 h at room temperature, the
reaction was concentrated under reduced pressure. The residue
was dissolved in EtOAc (60 mL) and washed with 0.1 M HCl (2
30 mL) followed by brine (1  30 mL). The organic layer was
concentrated to afford 5-[(2,5-dioxopyrrolidin-1-yl)oxy]-
5-oxopentanoic acid (20) (592 mg) as a colourless oil, which was
used without further purication. The prepared NHS ester (20)
(500 mg, 2.183 mmol, 1 equiv.) was then dissolved in anhydrous
DCM (10 mL) under an atmosphere of N2 and cooled in an ice
bath. Oxalyl chloride (225 mL, 2.621 mmol, 1.2 equiv.) was then
added followed by one drop of DMF. The resultant reaction
mixture was allowed to return to room temperature and stirred
for 16 h, aer which it was concentrated under reduced pres-
sure to afford the acid chloride. In a separate ask, cephalexin
monohydrate (598 mg, 1.637 mmol, 0.75 equiv.) was suspended
in anhydrous MeCN (20 mL) then anhydrous pyridine (329 mL,
4.093 mmol, 1.9 equiv.) was added. The previously prepared
acid chloride was then dissolved in anhydrous MeCN (10 mL)
and added to the cephalexin/pyridine mixture. The reaction was
then stirred at room temperature for 24 h aer which it was
concentrated under reduced pressure and the residue was trit-
urated in EtOAc to afford a cream solid. The solid was then
recrystallised from MeCN to afford (6R,7R)-7-[(2R)-2-{5-
[(2,5-dioxopyrrolidin-1-yl)oxy]-5-oxo
pentanamido}-2-phenylacetamido]-3-methyl-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (6) (501 mg, 52%
over 3 steps) as a cream solid. 1H NMR (400 MHz, DMSO-d6)
d 9.27 (dd, J ¼ 8.3, 3.1 Hz, 1H), 8.57 (dd, J ¼ 21.1, 8.1 Hz, 1H),
7.43 (d, J ¼ 7.1 Hz, 1H), 7.38–7.25 (m, 3H), 5.67 (d, J ¼ 8.0 Hz,
1H), 5.61 (dd, J ¼ 8.3, 4.6 Hz, 1H), 4.95 (d, J ¼ 4.6 Hz, 1H), 3.46
(d, J ¼ 18.5 Hz, 1H), 3.27 (d, J ¼ 18.3 Hz, 1H), 2.81 (s, 4H), 2.73–
2.63 (m, 2H), 2.33 (t, J ¼ 7.3 Hz, 2H), 2.27–2.16 (m, 2H), 1.98 (s,
3H). 13C NMR (101 MHz, DMSO-d6) d 171.2, 170.9, 170.3, 168.8,
168.5, 164.1, 163.5, 138.2, 129.8, 128.2, 127.6, 127.2, 122.7, 58.4,
57.2, 55.7, 33.4, 29.7, 28.9, 25.5, 20.5, 19.4. HRMS: exact mass
calculated for [M + Na]+ (C25H26N4NaO9S) requires m/z
581.1313, measured m/z 581.1322. IR (neat): 3286, 2945, 1776,
1728, 1643, 1524, 1360, 1204, 1158, 1066 cm1. QNMR purity
(1H NMR, maleic acid reference, DMSO-d6): 90%.
Preparation of 7. (6R,7R)-7-[(2R)-2-(4-Carboxybutanamido)-
2-phenylacetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic acid. A solution of cephalexin mono-
hydrate (100 mg, 0.274 mmol, 1 equiv.) and Et3N (46 mL,
0.329 mmol, 1.2 equiv.) was stirred at room temperature for
10 min. Glutaric anhydride (19) (38 mg, 0.329 mmol, 1.2 equiv.)
was then added and the resultant reaction mixture stirred for
3 h at room temperature. The reaction mixture was then
concentrated under reduced pressure to afford a yellow solid,
which was then triturated using 10% DCM/diethyl ether to
afford the Et3N salt of (6R,7R)-7-[(2R)-2-(4-carboxybutanamido)-
2-phenylacetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic acid (7) (144 mg, 94%), as a cream solid.
1HNMR (400MHz, acetonitrile-d3) d 8.18 (t, J¼ 8.4 Hz, 1H), 7.58
(t, J ¼ 8.5 Hz, 1H), 7.44–7.36 (m, 2H), 7.35–7.27 (m, 3H), 5.77
(dd, J¼ 7.7, 4.3 Hz, 1H), 5.61 (dd, J¼ 9.2, 4.7 Hz, 1H), 4.83 (d, J¼
4.7 Hz, 1H), 3.39 (d, J ¼ 17.4 Hz, 1H), 3.11–2.98 (m, 7H), 2.37–
2.24 (m, 4H), 1.87 (s, 3H), 1.84–1.73 (m, 2H), 1.22 (t, J ¼ 7.3 Hz,
9H). 13C NMR (101 MHz, DMSO-d6) d 174.4, 171.6, 170.9, 165.4,
162.8, 138.4, 128.2, 127.9, 127.5, 127.2, 58.1, 56.9, 55.6, 45.0,
34.1, 33.3, 28.5, 20.8, 19.3, 9.0. HRMS: exact mass calculated for
[M + H]+ (C21H24N3O7S) requires m/z 462.1329, measured m/z
462.1331. IR (neat): 3260, 2987, 1770, 1682, 1635, 1532, 1383,
1351, 1276, 1208, 1154 cm1. HPLC purity (254 nm): 95%.
Preparation of 8. (6R,7R)-7-[(2R)-2-Acetamido-2-phenyl
acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid. A solution of cephalexin monohydrate (200 mg,
0.548 mmol, 1 equiv.) and DIPEA (143 mL, 0.822 mmol, 1.5 equiv.)
was stirred at room temperature for 10min. Acetic anhydride (62 mL,
0.658 mmol, 1.2 equiv.) was then added and the resultant reaction
mixture was stirred at room temperature for 4 h. The reaction
mixture was then concentrated under reduced pressure to afford
a cream solid, which was then triturated using diethyl ether to
afford (6R,7R)-7-[(2R)-2-acetamido-2-phenylacetamido]-3-met
hyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (8)
(220 mg, quantitative) as a white solid. 1H NMR (400 MHz, DMSO-
d6) d 9.26 (d, J ¼ 8.3 Hz, 1H), 8.59 (d, J ¼ 8.4 Hz, 1H), 7.43 (d, J ¼
6.9 Hz, 2H), 7.36–7.22 (m, 3H), 5.69 (d, J¼ 8.3 Hz, 1H), 5.55 (dd, J¼
8.3, 4.6 Hz, 1H), 4.91 (d, J ¼ 4.7 Hz, 1H), 3.41 (d, J ¼ 17.5 Hz, 1H),
3.19 (d, J ¼ 17.9 Hz, 1H), 1.94 (s, 3H), 1.91 (s, 3H). 13C NMR (101
MHz, DMSO-d6) d 170.9, 169.0, 164.0, 163.5, 138.4, 128.2, 127.6,
127.2, 58.3, 57.1, 55.6, 28.7, 22.4, 19.4. Two carbon resonances not
observed/coincident. HRMS: exact mass calculated for [M + H]+
(C18H20N3O5S) requires m/z 390.1116, measured m/z 390.1115. IR
This journal is © The Royal Society of Chemistry 2020 RSC Adv., 2020, 10, 36485–36494 | 36491
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(neat): 3283, 1761, 1640, 1538, 1497, 1374, 1298, 1188, 1125 cm1.
HPLC purity (254 nm): 98%.
Preparation of 9. (6R,7R)-7-[(2R)-2-{[(Tert-butoxy)carbonyl]
amino}-2-phenylacetamido]-
3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
acid. A solution of cephalexin monohydrate (500 mg,
1.370 mmol, 1 equiv.) and Et3N (190 mL, 1.370 mmol, 1 equiv.)
was stirred at room temperature for 10 min. Boc2O (388 mg,
1.781 mmol, 1.3 equiv.) was then added and the resultant
reaction mixture was stirred at room temperature for 3 h. The
reactionmixture was then concentrated under reduced pressure
and the residue dissolved in DCM (20 mL). This organic solu-
tion was then washed with 0.1 M HCl (2  20 mL) and brine (1
 20 mL). The organic layer was collected, dried (MgSO4) and
concentrated under reduced pressure. The residue was then
triturated using diethyl ether to afford (6R,7R)-7-[(2R)-2-
{[(tert-butoxy)carbonyl]amino}-2-phenylacetamido]-
3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
acid (9) (608 mg, 93%) as a cream solid. 1H NMR (400 MHz,
chloroform-d) d 9.57 (s, 1H), 7.45–7.23 (m, 5H), 7.18 (s, 1H), 6.07
(d, J¼ 7.2 Hz, 1H), 5.65 (s, 1H), 5.34 (d, J¼ 7.3 Hz, 1H), 4.90 (d, J
¼ 4.5 Hz, 1H), 3.38 (d, J¼ 18.3 Hz, 1H), 3.03 (d, J¼ 18.4 Hz, 1H),
2.09 (s, 3H), 1.40 (s, 9H). 1H consistent with previously reported
data.38 13C NMR (101 MHz, chloroform-d) d 171.1, 164.2, 163.7,
155.8, 138.0, 131.9, 129.1, 128.6, 127.4, 122.6, 81.1, 59.2, 57.9,
57.6, 30.3, 28.4, 20.1. HRMS: exact mass calculated for [M + H]+
(C21H26N3O6S) requires m/z 448.1537, measured m/z 448.1546.
IR (neat): 3324, 2977, 1771, 1682, 1496, 1454, 1366, 1237, 1160,
1049 cm1. HPLC purity (254 nm): 98%.
Preparation of 10. (6R,7R)-7-[(2R)-2-(5-Aminopentanamido)-
2-phenylacetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylic acid. To a stirred solution of 5-(Boc-
amino)pentanoic acid (21) (1 g, 4.608 mmol, 1 equiv.) in anhy-
drous DCM (30 mL, 0.2 M) at 0 C, was added NHS (583 mg,
5.069 mmol, 1.1 equiv.). A solution of DCC (1.2 g, 5.991 mmol,
1.3 equiv.) in DCM (10 mL) was added slowly. The reaction
mixture was then allowed to warm to room temperature. Aer
16 h, the reaction was ltered and the lter cake washed with
DCM. The ltrate was concentrated under reduced pressure and
the residue was puried by column chromatography, eluting
with 10–60% EtOAc/petroleum ether, to afford a white oil.
Trituration in diethyl ether afforded 2,5-dioxopyrrolidin-1-yl 5-
{[(tert-butoxy)carbonyl]amino}pentanoate (22) (1.37 g, 95%) as
a white solid. 1H NMR (400 MHz, chloroform-d) d 4.59 (br. s,
1H), 3.16 (q, J ¼ 6.7 Hz, 2H), 2.84 (d, J ¼ 3.7 Hz, 4H), 2.64 (t, J ¼
7.3 Hz, 2H), 1.78 (p, J¼ 7.4 Hz, 2H), 1.60 (p, J¼ 7.0 Hz, 2H), 1.44
(s, 9H). 1H is consistent with previously reported data.39 13C
NMR (101 MHz, chloroform-d) d 169.3, 168.6, 156.1, 79.4, 40.0,
34.1, 29.2, 28.5, 25.7, 25.1, 21.9. HRMS: exact mass calculated
for [M + H]+ (C14H22N2NaO6) requires m/z 337.1370, measured
m/z 337.1371. IR (neat): 3318, 2975, 2932, 2851, 1812, 1777,
1726, 1682, 1626, 1572, 1514, 1364, 1274, 1201, 1170, 1069,
1056, 1008 cm1.
Et3N (114 mL, 0.822 mmol, 1.5 equiv.) was added to
a suspension of cephalexin monohydrate (200 mg, 0.548 mmol,
1 equiv.) in MeCN (50 mL). Aer 5 min dissolution occurred to
give a yellow solution. 2,5-Dioxopyrrolidin-1-yl 5-{[(tert-butoxy)
carbonyl]amino}pentanoate (22) (258 mg, 0.822 mmol, 1.5
equiv.) was then added and the reaction was allowed to stir at
room temperature for 16 h. The reaction mixture was concen-
trated under reduced pressure and the residue dissolved in
EtOAc. The organic solution was washed with 0.01 M HCl (3 
20 mL), then dried (MgSO4), and concentrated under reduced
pressure to afford a pale yellow solid. Trituration in diethyl
ether afforded (6R,7R)-7-[(2R)-2-(5-{[(tert-butoxy)carbonyl]
amino}pentanamido)-2-phenylacetamido]-
3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
acid (23) (169 mg, 56%) as a cream solid. 1H NMR (400 MHz,
DMSO-d6) d 9.27 (d, J¼ 8.3 Hz, 1H), 8.49 (d, J¼ 8.3 Hz, 1H), 7.41
(d, J ¼ 7.2 Hz, 2H), 7.34–7.22 (m, 3H), 6.77 (t, J ¼ 5.7 Hz, 1H),
5.67 (d, J¼ 8.2 Hz, 1H), 5.60 (dd, J¼ 8.3, 4.6 Hz, 1H), 4.94 (d, J¼
4.6 Hz, 1H), 3.45 (d, J ¼ 18.3 Hz, 1H), 3.27 (d, J ¼ 18.3 Hz, 1H),
2.86 (q, J¼ 6.6 Hz, 2H), 2.18 (t, J ¼ 7.3 Hz, 2H), 1.97 (s, 3H), 1.44
(p, J¼ 7.0 Hz, 2H), 1.35 (s, 9H), 1.33–1.27 (m, 2H). 13C NMR (101
MHz, DMSO-d6) d 172.0, 170.9, 164.1, 163.5, 155.6, 138.4, 129.8,
128.2, 127.6, 127.1, 122.7, 77.4, 58.4, 57.2, 55.5, 47.5, 34.6, 29.2,
28.9, 28.3, 22.7, 19.4. HRMS: exact mass calculated for [M + Na]+
(C26H34N4NaO7S) requires m/z 569.2040, measured m/z
569.2041. IR (neat): 3284, 2931, 1764, 1639, 1520, 1452, 1364,
1221, 1164, 1067, 1040 cm1.
To a solution of (6R,7R)-7-[(2R)-2-(5-{[(tert-butoxy)carbonyl]
amino}pentanamido)-2-phenylacetamido]-3-methyl-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (23) (100 mg,
0.183 mmol, 1 equiv.) in DCM (4 mL, 0.04 M) was added and
0.1mL triethyl silane followed by 0.5mLTFA. The reactionmixture
was stirred at room temperature for 3 h, aer which it was
concentrated to an orange oil. The residue was then azeotroped
with DCM (3  10 mL) to afford a cream solid. This solid was
triturated with diethyl ether to afford (6R,7R)-7-[(2R)-
2-(5-aminopentanamido)-2-phenylacetamido]-3-methyl-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (10) (77 mg,
94%) as a cream solid. 1HNMR (400 MHz, DMSO-d6) d 9.31 (d, J¼
8.4 Hz, 1H), 8.57 (d, J ¼ 8.2 Hz, 1H), 7.67 (br. s, 2H), 7.47–7.41 (m,
2H), 7.35–7.26 (m, 3H), 5.69 (d, J ¼ 8.2 Hz, 1H), 5.62 (dd, J ¼ 8.4,
4.6 Hz, 1H), 4.96 (d, J¼ 4.7 Hz, 1H), 3.47 (d, J¼ 18.8 Hz, 1H), 3.28
(d, J¼ 18.2 Hz, 1H), 2.77 (br. s, 2H), 2.31–2.22 (m, 2H), 1.98 (s, 3H),
1.59–1.48 (m, 4H). 13C NMR (101 MHz, DMSO-d6) d 171.6, 170.9,
164.1, 163.5, 138.3, 129.6, 128.2, 127.6, 127.1, 122.7, 58.4, 57.2,
55.5, 38.7, 34.1, 28.9, 26.7, 22.1, 19.4. HRMS: exact mass calculated
for [M + H]+ (C21H27N4O5S) requires m/z 447.1697, measured m/z
447.1698. IR (neat): 3250, 3050, 2939, 1763, 1639, 1525, 1363, 1184,
1130, 1070 cm1. HPLC purity (254 nm): 97%.
Biology
Materials. AmpC (Uniprot ID: P00811) was purchased from
Abcam plc (Cambridge, UK). PBP4 (Uniprot ID: P32959) was
purchased from Generon (Slough, UK).
Expression and purication of PBP3. A truncated version of
the sI gene formed of residues W44-S588, encoding only the
soluble domain, was amplied from E. coli BW25113. The
resulting construct was inserted into the vector pBADnLIC2005,40
introducing an N-terminal deca-histidine tag when expressed.
The resulting vector was transformed into E. coli MC1061 for
36492 | RSC Adv., 2020, 10, 36485–36494 This journal is © The Royal Society of Chemistry 2020
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expression. Cultures for protein expression were grown in 1 L of
Luria–Bertani (LB) broth at 37 C on an orbital shaker. Expression
was induced by addition of 0.01% L-arabinose during mid-log
phase of growth. Cultures were further incubated for 16 h at
20 C, then the cells were harvested by centrifugation. Cell pellets
were resuspended in 50 mM KPi pH 7.8, 200 mM NaCl, 10 mM
imidazole, 20% glycerol with 1 mM phenylmethylsulfonyl uo-
ride followed by sonication. The lysate was claried by centrifu-
gation before loading onto a HisTrap HF column (GE
Healthcare). To remove any pre-bound ligands, refolding puri-
cation was performed by initially washing with the protein
unfolding buffer [2 M guanidine HCl, 50 mM KPi (pH 7.8),
200 mM NaCl, 20% glycerol, and 20 mM imidazole] and then
performing a gradient wash to the protein refolding buffer
[50 mM KPi (pH 7.8), 200 mM NaCl, 20% glycerol, and 20 mM
imidazole] before the elution of the protein using the elution
buffer [50 mM KPi (pH 7.8), 200 mM NaCl, 20% glycerol, and
500 mM imidazole]. The eluted protein was buffer-exchanged to
the buffer 50 mM KPi (pH 7.8), 200 mM NaCl using a HisTrap
Desalting (GE Healthcare) column.
Thermal shi assay. The thermal shi assay was carried out
using the Protein Thermal Shi™ assay kit (Applied Bio-
systems). 3 mM of puried E. coli PBP3 was incubated with the b-
lactam analogues at 300 mM concentration in a mixture con-
taining the Protein Thermal Shi™Dye. The samples were then
heated in a StepOnePlus™ Real-Time PCR System from 25 to
95 C at a rate of 1 C min1. Tests were carried out in triplicate
and the averages plotted as the negative rst derivative vs.
temperature. Reference wells, i.e. solutions consisting only of
only PBP3 with dye, PBP3 only, and dye only, were used as
controls. Melting temperature (Tm) values were determined with
and without each compound, and the change in melting
temperature (DTm) was obtained, Fig. 2. The thermal shi assay
with PBP4 was carried out using the protocol described for
PBP3, with the follow deriviatisation: 500 nM of puried Bacillus
subtilis PBP4 was incubated with 50 mM of the b-lactam
analogues.
To determine the approximate affinity of PBP3 for
compounds 1 to 12, 2 mM of puried E. coli PBP3 was incubated
with a range of concentrations of each compound. The mixtures
were incubated at room temperature for 25 minutes prior to the
start of the protein thermal shi assay program on the qPCR
machine. The signals from the hydrophobic uorescent dye
were monitored as the mixtures were heated from 35 to 70 C at
a ramp rate of 0.3%. The Tm values of PBP3 incubated with each
compound at the various concentrations were recorded. The
relative changes in the Tm values, relative to the highest Tm
change seen for each compound, are reported as a ratio in the
ESI.† The concentration at which the Tm rose to >Tm1/2 was used
to approximate the relative affinities.
Expression and purication of TEM-1. TEM-1 (Uniprot ID:
A5PHA6) was cloned into pBKR, a pBADcLIC2005 derivative
with a kanamycin resistance cassette in place of the ampicillin
resistance cassette. The resulting plasmid, pBKR-TEM1, was
transformed into the expression strain E. coli MC1061. Starting
cultures were grown in 10 mL LB broth at 37 C overnight with
shaking. A litre of expression culture was prepared and grown to
an OD600 of between 0.4–0.6 before induction with 0.01% (w/v)
L-arabinose. The induced culture was allowed to grow for 18 h at
30 C. The resulting culture was harvested by centrifugation at
5000g. The pellet was then resuspended in 30 mL of sterile SET
buffer (0.5 M sucrose, 5 mM EDTA, 50 mM Tris–HCl pH 7.8).
13 mg of lysozyme was added to the mixture before incubation
for 1 h at 30 C. To isolate the periplasmic fraction, the treated
sample was then claried by centrifugation at 27 000g. The
supernatant was dialysed into 50 mM KPi pH 7.8, 200 mM NaCl
over 18 hours at 4 C. Aer dialysis, the periplasmic fraction was
loaded onto an equilibrated 5 mL HisTrap column. The bound
His-tagged TEM-1 were washed with 10 column volumes of
wash buffer (50 mM KPi pH 7.8, 200 mM NaCl, 20% glycerol,
40 mM imidazole). To elute the bound protein, 5 column
volumes of elution buffer (50 mM KPi pH 7.8, 200 mM NaCl,
20% glycerol, 500 mM imidazole) was owed through the
column while collecting the ow through. For downstream
analysis, the protein was buffer exchanged into 50 mM KPi pH
7.8, 200 mM NaCl using the HisTrap desalting column.
Expression and purication of CTX-M-15. CTX-M-15 (Uni-
prot ID: Q9EXV5) was synthesised using the protocol described
above in the expression and purication of TEM-1, with the
following deviations: the gene coding for NDM-1 was syn-
thesised as a gBlock (IDT). Following induction with L-arabi-
nose, 1 L cultures were incubated for 20 h at 20 C.
Expression and purication of NDM-1. NDM-1 (Uniprot ID:
C7C422, residues G29-R270) was synthesised using the protocol
described above in the expression and purication of TEM-1,
with the following deviations: the gene coding for NDM-1 was
synthesised as a gBlock (IDT). Following induction with L-
arabinose, 1 L cultures were incubated for 20 h at 20 C.
Enzyme kinetics. The rate of b-lactamase-mediated hydro-
lysis was montiored using a previously reported absorbance
assay.19 In a 96-well plate, 200 mL of the test compounds at the
desired concentrations with the relevant b-lactamases were
incubated and the absorbance at 260 nm was monitored.
Experiments using NDM-1 included 1 equivalent of ZnCl2. All
studies were carried out using one batch of puried enzyme.
Experiments were carried out at 37 C and measurements were
taken every 60 s (Epoch 2 Microplate Spectrophotometer, Bio-
Tek) for 1 h. Each sample was carried out in triplicate and the
average was used for further calculations. kcat/Km was deter-
mined from v ¼ (kcat/Km)[E][S]. The initial velocity for each
compound was determined and used as “v”.
MIC growth assay. Stock solutions of each compound were
prepared in 50% DMSO/water at 100 the nal concentration.
In a 96-well plate, 2 mL of the test compounds were added to
each well. Each plate included the positive control (750 mg mL1
chloramphenicol), the negative control (50% DMSO/water) and
media only wells. To each test well was then added 198 mL of the
required bacteria stock (OD 0.05). E. coli assays were carried out
using LB broth, S. aureus were carried out using tryptic soy
broth (TSB). Plates were incubated at 37 C and the OD600 was
measured (Epoch 2 Microplate Spectrophotometer, BioTek)
every 30 min over a 17 h period. Tests were carried out in trip-
licate, the background absorbance was removed using reference
wells, and the averages were determined. Dose curves were
This journal is © The Royal Society of Chemistry 2020 RSC Adv., 2020, 10, 36485–36494 | 36493
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plotting using the OD600 aer 16 h growth vs. compound
concentration. MICs were dened as the minimum concentra-
tion of compound at which no signicant growth was observed
aer 16 h incubation. MIC values were determined using
GraphPad Prism (version 8.3.0).
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